Santhera的Raxone在MS试验中失败。

2018-03-06 MedSci MedSci原创

Santhera公司在其主要的线粒体疾病治疗idebenone上遭受了更多的坏消息,因为它未能在一个评估其多发性硬化症潜在能力的试验中击中目标。这种药物以商标名Raxone出售,用于治疗罕见病Leber氏遗传性视神经病变(LHON)患者,在原发性进行性多发性硬化患者的疾病进展中未显示与安慰剂有任何区别。I / II期临床试验部分由美国国立卫生研究院NIH国家神经疾病和卒中研究所赞助,共有77名患者

Santhera公司在其主要的线粒体疾病治疗idebenone上遭受了更多的坏消息,因为它未能在一个评估其多发性硬化症潜在能力的试验中击中目标。这种药物以商标名Raxone出售,用于治疗罕见病Leber氏遗传性视神经病变(LHON)患者,在原发性进行性多发性硬化患者的疾病进展中未显示与安慰剂有任何区别。I / II期临床试验部分由美国国立卫生研究院NIH国家神经疾病和卒中研究所赞助,共有77名患者参加,其中66名完成了一项为期一年的观察性预处理阶段的试验,其次是为期两年的安慰剂对照干预期。数据分析显示,治疗组在疾病进展方面没有差异。另一方面,治疗组间不良事件的发生率和严重程度也没有差异,表明药物的高剂量比目前市售的LHON的耐受性好。"显然,小样本量是研究这种复杂且持续进展的神经系统疾病的治疗干预的一个局限,"Santhera首席执行官Thomas Meier博士评论到。就在几周前,该药物被欧洲药物管理局(European drug Agency advisors)拒绝接受,作为治疗Duchenne肌营养不良症(DMD)的药物。人用药品委员会(CHMP)的结论是,目前的证据不能批准对D

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738875, encodeId=a81b1e3887599, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Mar 15 11:20:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293633, encodeId=b7412936333f, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Mar 06 20:29:59 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293632, encodeId=b8c32936327b, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Mar 06 20:28:08 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1738875, encodeId=a81b1e3887599, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Mar 15 11:20:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293633, encodeId=b7412936333f, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Mar 06 20:29:59 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293632, encodeId=b8c32936327b, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Mar 06 20:28:08 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
    2018-03-06 清风拂面

    谢谢分享学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1738875, encodeId=a81b1e3887599, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Mar 15 11:20:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293633, encodeId=b7412936333f, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Mar 06 20:29:59 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293632, encodeId=b8c32936327b, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Mar 06 20:28:08 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
    2018-03-06 清风拂面

    谢谢分享学习

    0